<div id="readability-page-1"><p>Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $13.28 and last traded at $13.75, with a volume of 2168574 shares. The stock had previously closed at $13.65.</p><div><p><span></span><span>Get <strong>Janux Therapeutics</strong> alerts:</span></p></div><h2>Wall Street Analysts Forecast Growth</h2><p>Several brokerages have weighed in on JANX. Truist Financial assumed coverage on Janux Therapeutics in a research note on Wednesday, September 10th. They set a &#34;buy&#34; rating and a $100.00 target price on the stock. Wolfe Research began coverage on Janux Therapeutics in a report on Tuesday, November 18th. They set a &#34;peer perform&#34; rating on the stock. Cantor Fitzgerald cut their price objective on shares of Janux Therapeutics from $200.00 to $150.00 and set an &#34;overweight&#34; rating on the stock in a research note on Tuesday, December 2nd. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Janux Therapeutics in a report on Wednesday, October 8th. Finally, Barclays decreased their target price on shares of Janux Therapeutics from $48.00 to $29.00 and set an &#34;overweight&#34; rating for the company in a research report on Wednesday, December 17th. Twelve analysts have rated the stock with a Buy rating, two have given a Hold rating and one  has issued  a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $61.08.</p><p><b>Read Our Latest Stock Report on JANX</b></p><h2>Janux Therapeutics Price Performance</h2><p>The company has a fifty day moving average price of $22.23 and a two-hundred day moving average price of $23.69. The firm has a market cap of $827.06 million, a price-to-earnings ratio of -8.18 and a beta of 2.88. </p><p>Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.60) by $0.21. The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million.  On average, research analysts expect that  Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year. </p><h2>Insiders Place Their Bets</h2><p>In related news, CEO David Alan Campbell sold 8,072 shares of the business's stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $110,828.56. Following the sale, the chief executive officer directly owned 284,982 shares in the company, valued at $3,912,802.86. The trade was a 2.75% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, insider Zachariah Mciver sold 2,714 shares of the firm's stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $37,263.22. Following the sale, the insider owned 23,286 shares of the company's stock, valued at $319,716.78. The trade was a 10.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 42,364 shares of company stock worth $972,185. Company insiders own  29.40% of the company's stock. </p><h2>Institutional Investors Weigh In On Janux Therapeutics</h2><p>Large investors have recently modified their holdings of the stock. Osaic Holdings Inc. raised its position in shares of  Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company's stock worth $80,000 after purchasing an additional 3,037 shares during the period.  Virtus Investment Advisers LLC boosted its position in shares of  Janux Therapeutics by 37.9% in the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company's stock valued at $85,000 after purchasing an additional 1,011 shares during the period.  Tower Research Capital LLC TRC increased its stake in  Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company's stock worth $91,000 after purchasing an additional 2,502 shares in the last quarter.  Ameritas Investment Partners Inc. raised its holdings in  Janux Therapeutics by 25.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company's stock worth $93,000 after buying an additional 820 shares during the period.  Finally, Winthrop Capital Management LLC acquired a new stake in  Janux Therapeutics during the 3rd quarter worth about $106,000. 75.39% of the stock is owned by institutional investors. </p><h2>About Janux Therapeutics</h2> (Get Free Report)<p>Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX. </p><p>Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Janux Therapeutics</li><li>A month before the crash</li><li>BNZI: BNZI Surges Ahead as AI Marketing Fuels Record Revenue</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>A Message From An Ex-CIA Officer About Trump</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Janux Therapeutics Right Now?</h2><p>Before you consider Janux Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.</p><p>While Janux Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

JANX

<p>Janux Therapeutics (NASDAQ:JANX) shares hit a new 12-month low at $13.28 during trading, closing at $13.75. Analysts have mixed views, with Truist Financial rating it a "buy" with a $100 target, while Weiss Ratings maintains a "sell" rating. The company reported earnings of ($0.39) per share, exceeding estimates, with revenue of $10 million. Insiders have sold shares recently, and institutional investors hold 75.39% of the stock. The average analyst rating is "Moderate Buy" with a consensus target price of $61.08.</p>

Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month Low - What's Next?